In 2022, the venture capital funding for life sciences in Europe continues to weaken, further widening the gap to 2021 (EUR 9.4bn vs. EUR 6.5bn). The cumulative financing volume in August 2022 falls by more … Read more
After an exceptional year 2021 for venture capital funding in the US Biotech-sector, aggregated financing volumes in 2022 are for the first time lower than in 2021. During the last months funding volumes have declined … Read more
The FCF Life Sciences team continuously analyses the current sentiments in the European life sciences venture capital funding sector. For August ’22, venture capital funding continues to decline. All life sciences subsectors (i.e. Biotech, HealthTech, … Read more
Transaction volumes and the number of closed deals in the AgriTech space continued their steady growth in the US and massively surged in Europe. In the US, VC financing volumes in AgriTech more than doubled … Read more
The significant growth of transaction volumes and the number of deals closed from 2017 to 2021 confirms the increasing importance of longevity in the US and Europe. For both markets, the number of deals almost … Read more
Genomics represents the most crucial pillar in the ‘OMX-space and is the largest subsector in the US and Europe (EUR 13.3bn vs. EUR 1.8bn). The second and third largest subsectors are microbiomics and proteomics for … Read more
A recent FCF Life Sciences analysis showed a significant decline in funding volumes for European life sciences markets in the first half of 2022 compared to 2021. This trend is now confirmed for the US … Read more
During the first six months of 2022, we find that the funding for life sciences markets declined significantly compared to 2021. The trend affects all relevant life sciences subsectors of Biotech, HealthTech, and MedTech. The … Read more
Venture capital deal volumes in the European life sciences sector reached a record-breaking level in 2021. However, financing volumes decreased significantly by 29% in the first four months of 2022 compared to 2021. Our … Read more
With 44 deals, the corporate venture arm of Boehringer Ingelheim was the most active corporate investor in the European life science market in the last five years. The only other investor having reached the top … Read more
